ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO301

Efficacy and Safety of Patiromer in Participants with Diabetes: A Pooled Analysis

Session Information

Category: Fluid and Electrolytes

  • 902 Fluid and Electrolytes: Clinical

Authors

  • Rossignol, Patrick, Clinical Investigation Center-INSERM-CHU of Nancy, VANDOEUVRE LES NANCY, France
  • Gross, Coleman, Relypsa Inc., a Vifor Pharma Group Company, Redwood City, California, United States
  • Mayo, Martha, Relypsa Inc., a Vifor Pharma Group Company, Redwood City, California, United States
  • Warren, Suzette, Relypsa Inc., a Vifor Pharma Group Company, Redwood City, California, United States
  • Yuan, Jinwei, Relypsa Inc., a Vifor Pharma Group Company, Redwood City, California, United States
  • Budden, Jeffrey J., Relypsa Inc., a Vifor Pharma Group Company, Redwood City, California, United States
  • Bakris, George L., The University of Chicago Medicine, Chicago, Illinois, United States
Background

The purpose of this post-hoc pooled analysis was to assess the efficacy and safety of patiromer (PAT) for treatment of hyperkalemia in participants with and without diabetes mellitus (DM+ and DM-).

Methods

We analyzed pooled data through Week 4 (Wk4) from 3 trials of PAT. Study participants who took ≥1 PAT dose and had ≥1 post-baseline (BL) serum potassium (sK) measurement were included. Participants were stratified according to DM+ and DM-, and assessed for: sK change from BL at Wk4, sK over time, and % with any sK measurement in target range (3.8–5.0 mEq/L).

Results

653 participants were included; 82% DM+ (mean BL HbA1c and DM duration: 7.4% and 14 years, respectively). Mean BL sK and eGFR were 5.4 mEq/L and 40.3 mL/min/1.73m2 in DM+, and 5.5 mEq/L and 34.8 mL/min/1.73m2 in DM-. At Wk4, overall mean (SE) sK change from BL was -0.72 (0.02) in DM+ and -0.88 (0.06) in DM- (Figure). In participants with BL sK ≥5.5 mEq/L, mean (SE) sK changes at Wk4 were -1.01 (0.05) in DM+ and -1.21 (0.10) in DM-, and -0.52 (0.03) and -0.51 (0.08), respectively, in DM+ and DM- participants who had BL sK <5.5 mEq/L. Regardless of BL sK status, >95% of all DM+ and DM- participants achieved any sK measurement in the target range through Wk4. The presence or absence of heart failure or eGFR <45 mL/min/1.73m2 did not impact these results. At least 1 adverse event (AE) was reported in 31% of DM+ and 38% of DM- participants, most commonly (≥2%) constipation, diarrhea, hypomagnesemia (hypoMg), and nausea. AEs of hypoMg were reported in 2% of both DM+ and DM- participants. Lab values of Mg <1.4 mg/dL occurred in 5% and 1% of DM+ and DM- participants, respectively. Use of proton pump inhibitors and/or loop diuretics was common (43%) in those who experienced low serum Mg.

Conclusion

In this post-hoc analysis of pooled data, PAT was equally effective and well-tolerated in DM+ and DM- participants.

Figure

Funding

  • Commercial Support